Research Article
Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma
Table 1
Patients’ demographics,
.
| Age (range) | 56.4 (23.4–85.4) | Tumor size (range) | 9 (2–30) | Number of metastatic sites (range) | 2 (1–8) | Presentation status | | Primary disease | 132 (61) | Metastatic disease | 83 (39) | Gender | | Female | 135 (63) | Male | 80 (37) | Primary tumor size | | <5 cm | 34 (16) | 5–10 cm | 81 (38) | >10 cm | 80 (37) | Unknown primary | 10 (5) | Known primary, unknown size | 10 (5) | KPS | | 60 | 2 (1) | 70 | 8 (4) | 80 | 46 (21) | 90 | 65 (30) | 100 | 22 (10) | Unknown | 72 (33) | Primary site | | A/P or RP | 151 (70) | Extremity | 45 (21) | Trunk | 9 (4) | Unknown primary | 10 (5) | Margins | | Negative | 95 (44) | Positive | 45 (21) | Gross disease | 3 (1) | N/A—no surgery | 47 (22) | Unknown | 25 (12) | Grade | | Low | 7 (3) | Intermediate | 5 (2) | High | 176 (82) | Unknown | 27 (14) | Depth | | Superficial | 5 (2) | Deep | 196 (91) | Unknown | 14 (7) | Number of metastatic sites | | <3 | 144 (67) | ≥3 | 71 (33) | Lung metastases | | No | 102 (47) | Yes | 113 (53) | Liver metastases | | No | 159 (74) | Yes | 56 (26) |
|
|
Numbers may not add to 100 due to rounding. KPS: Karnofsky Performance Status; A/P: abdomen/pelvis, RP: retroperitoneal; and N/A: not applicable.
|